Bayer closed two 1bn biodollar deals within a timeframe of a few days. More recently Xofigo failed in a clinical trial and Bayer’s pharma division ‘lost’ its R&D veteran, Andreas Busch.
04 Dec 2017
Raising the pot - high enough?
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Raising the pot - high enough?
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
04 Dec 2017 -
Author:
Martin Schnee -
Pages:
3
Bayer closed two 1bn biodollar deals within a timeframe of a few days. More recently Xofigo failed in a clinical trial and Bayer’s pharma division ‘lost’ its R&D veteran, Andreas Busch.